(Q44552628)

4 December 2017

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. (English)

1 reference

4 December 2017

Ozmen Metin

1

1 reference

4 December 2017

Kemal Yazici

series ordinal

2

1 reference

4 December 2017

Senel Tot

series ordinal

3

1 reference

4 December 2017

Aylin Ertekin Yazici

series ordinal

4

1 reference

4 December 2017

1 August 2003

1 reference

4 December 2017

Human Psychopharmacology

1 reference

4 December 2017

18

1 reference

4 December 2017

463-467

1 reference

4 December 2017

6

1 reference

Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.

4 December 2017

1 reference

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.

21 January 2018

1 reference

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.

21 January 2018

1 reference

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

21 January 2018

1 reference

The epidemiology of obsessive-compulsive disorder in five US communities.

21 January 2018

1 reference

Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography.

21 January 2018

1 reference

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.

21 January 2018

1 reference

Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder.

21 January 2018

1 reference

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

21 January 2018

1 reference

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HUP.512

1 reference

4 December 2017

1 reference